ArticleCell biology and toxicology2020
CRISPR off-targets: a question of context.
Article in Cell biology and toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- PROTAC-mediated PCSK9 degradation attenuates atherosclerosis and improves plaque composition via suppression of NF-κB/TNF-α pathway.BMC medicine · 2026Article
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Library transgenesis in zebrafish through delayed site-specific mosaic integration for in vivo pooled screening of transgenes.bioRxiv : the preprint server for biology · 2026Article
- Weaponizing CRISPR/Cas9 for selective elimination of cells with an aberrant genome.DNA repair · 2025Article
- Off-target sequence variations driven by the intrinsic properties of the Cas-sgRNA-DNA complex in genome editing.PloS one · 2025Article
- CRISPR/Cas9 Protocols for Disrupting Gene Function in the Non-vertebrate Chordate Ciona.Integrative and comparative biology · 2024Review
- A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Correction of exon 2, exon 2-9 and exons 8-9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system.Scientific reports · 2024Article
- CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy.Journal of translational medicine · 2024Review
- A cleavage rule for selection of increased-fidelity SpCas9 variants with high efficiency and no detectable off-targets.Nature communications · 2023Article
- Dynamic observations of CRISPR-Cas target recognition and cleavage heterogeneities.Nanophotonics (Berlin, Germany) · 2022Article
- HaloChIP-seq for Antibody-Independent Mapping of Mouse Transcription Factor CistromesBio-protocol · 2022Article
- Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation.Acta neuropathologica communications · 2022Article
- The application of CRISPR /Cas mediated gene editing in synthetic biology: Challenges and optimizations.Frontiers in bioengineering and biotechnology · 2022Review
- An Outlook on Global Regulatory Landscape for Genome-Edited Crops.International journal of molecular sciences · 2021Review
- Discovery in clinical and translational medicine.Clinical and translational medicine · 2021Article
- One-Step Generation of Multiple Gene-Edited Pigs by Electroporation of the CRISPR/Cas9 System into Zygotes to Reduce Xenoantigen Biosynthesis.International journal of molecular sciences · 2021Article
- Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity.Genome biology · 2020Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.